Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis

被引:10
作者
Karyotakis, NC [1 ]
Anaissie, EJ [1 ]
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,INFECT DIS SECT,DEPT MED SPECIALTIES,HOUSTON,TX
关键词
D O I
10.1128/AAC.40.12.2907
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Candida lusitaniae may cause life-threatening infections in the immunocompromised host and may be resistant to amphotericin B. Flucytosine (5-FC) is very active against C. lusitaniae isolates in vitro, while the in vivo response of murine infection to 5-FC is not as good. To evaluate the hypothesis that this discrepancy may be primarily due to the short half-life of 5-FC in mice, we compared the same total dosage of 75 mg of 5-FC per kg of body weight per day given by bolus injections or infused continuously via a subcutaneously implanted pump in immunosuppressed CF1 mice infected with C. lusitaniae. The fungal titers in the kidneys of mice treated with the continuous 5-FC infusion were significantly lower (P less than or equal to 0.05) than those in the kidneys of mice that received bolus injections once or thrice daily. The antifungal activity of 5-FC against murine candidiasis is best evaluated when the drug is administered by continuous infusion.
引用
收藏
页码:2907 / 2908
页数:2
相关论文
共 10 条
[1]   OPPORTUNISTIC MYCOSES IN THE IMMUNOCOMPROMISED HOST - EXPERIENCE AT A CANCER CENTER AND REVIEW [J].
ANAISSIE, E .
CLINICAL INFECTIOUS DISEASES, 1992, 14 :S43-S53
[2]   FLUCONAZOLE SUSCEPTIBILITY TESTING OF CANDIDA-ALBICANS - MICROTITER METHOD THAT IS INDEPENDENT OF INOCULUM SIZE, TEMPERATURE, AND TIME OF READING [J].
ANAISSIE, E ;
PAETZNICK, V ;
BODEY, GP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) :1641-1646
[3]   CORRELATION BETWEEN IN-VITRO AND IN-VIVO ACTIVITY OF ANTIFUNGAL AGENTS AGAINST CANDIDA SPECIES [J].
ANAISSIE, EJ ;
KARYOTAKIS, NC ;
HACHEM, R ;
DIGNANI, MC ;
REX, JH ;
PAETZNICK, V .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (02) :384-389
[4]   EMERGENCE OF A NEW OPPORTUNISTIC PATHOGEN, CANDIDA-LUSITANIAE [J].
BLINKHORN, RJ ;
ADELSTEIN, D ;
SPAGNUOLO, PJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (02) :236-240
[5]  
DIGNANI MC, 1993, P C CAND CAND AM SOC
[6]   EVOLVING ROLE OF FLUCYTOSINE IN IMMUNOCOMPROMISED PATIENTS - NEW INSIGHTS INTO SAFETY, PHARMACOKINETICS, AND ANTIFUNGAL THERAPY [J].
FRANCIS, P ;
WALSH, TJ .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (06) :1003-1018
[7]  
GRAYBILL J, COMMUNICATION
[8]   FUNGEMIA IN THE IMMUNOCOMPROMISED HOST - CHANGING PATTERNS, ANTIGENEMIA, HIGH MORTALITY [J].
MEUNIERCARPENTIER, F ;
KIEHN, TE ;
ARMSTRONG, D .
AMERICAN JOURNAL OF MEDICINE, 1981, 71 (03) :363-370
[9]  
*NAT I HLTH, 1985, GUID CAR US LAB AN
[10]   CORRELATION OF INVITRO SUSCEPTIBILITY TEST-RESULTS WITH INVIVO RESPONSE - FLUCYTOSINE THERAPY IN A SYSTEMIC CANDIDIASIS MODEL [J].
STILLER, RL ;
BENNETT, JE ;
SCHOLER, HJ ;
WALL, M ;
POLAK, A ;
STEVENS, DA .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (06) :1070-1077